The combination treatment is being assessed to treat Non-Hodgkin’s lymphoma. Credit: Ed Uthman/ Flickr (Creative Commons).

China’s Center for Drug Evaluation (CDE) has granted approval for InnoCare Pharma to conduct a Phase II clinical trial of orelabrutinib along with tafasitamab + lenalidomide to treat Non-Hodgkin’s lymphoma (NHL).

The multi-cohort, single-arm, open-label clinical trial has been designed to assess the safety and efficacy of the combination to treat relapsed or refractory NHL patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Orelabrutinib developed the highly selective BTK inhibitor orelabrutinib to treat cancers and autoimmune diseases.

The China National Medical Products Administration (NMPA) granted conditional approval for orelabrutinib to treat relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL) and r/r mantle cell lymphoma (MCL) patients.

The BTK inhibitor is currently being evaluated in multi-centre, multi-indication clinical trials as monotherapy or in combination therapies, as first line treatment of MCD subtype of diffuse large B-cell lymphoma (DLBCL) in China and the US.

See Also:

Additionally, it is being assessed to treat Multiple Sclerosis (MS) in global phase II studies, and for the treatment of Systemic Lupus Erythematosus (SLE), Neuromyelitis Optica Spectrum Disorder (NMOSD), and Primary Immune Thrombocytopenia (ITP) in China.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

InnoCare co-founder, chairwoman and CEO Dr Jasmine Cui said: “We are dedicated to building a leading hematology-oncology franchise with orelabrutinib and tafasitamab + lenalidomide as backbone therapies.

“NHL remains an area of strong unmet medical need in China, and we will accelerate this clinical trial along with the registrational trial of tafasitamab in combination with lenalidomide for relapsed or refractory diffuse large B-Cell lymphoma (DLBCL) in China.”

Tafasitamab is a humanised Fc-modified cytolytic CD19-targeting immunotherapy.

The combination of tafasitamab and lenalidomide is approved by the Health Commission and Medical Products Administration of Hainan Province to treat eligible DLBCL patients, under the early access programme in Boao Lecheng International Medical Tourism Pilot Zone.